India Pharma Outlook Team | Friday, 20 March 2026
Pfizer Inc. has announced positive topline results from its phase 3 TALAPRO-3 study, highlighting the impact of Talzenna Xtandi trial outcomes in advanced prostate cancer.
The study evaluated Talzenna in combination with Xtandi in patients with HRR gene-mutated metastatic castration-sensitive prostate cancer (mCSPC).
The trial met its primary goal, showing a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared to placebo plus Xtandi. Results exceeded the pre-set hazard ratio target of 0.63, with most patients remaining progression-free at the time of analysis. Benefits were consistent across patients with both BRCA and non-BRCA HRR gene mutations.
“Current treatment approaches leave many patients with HRR gene-mutated metastatic castration-sensitive prostate cancer vulnerable to early disease progression,” said Neeraj Agarwal, M.D., FASCO, Professor and Presidential Endowed Chair of Cancer Research at Huntsman Cancer Institute at the University of Utah, and global lead investigator for TALAPRO-3. “The TALAPRO-3 results demonstrate that treatment with Talzenna in combination with Xtandi earlier in the disease course significantly extends the time patients can live without their cancer worsening.”
Also Read: Advancing Interventional Radiology in India Through Collaboration
In addition to rPFS, the combination showed a strong trend toward improved overall survival, along with gains in response rate, duration of response, and delayed PSA progression. Safety findings aligned with known profiles of both drugs, with no new concerns reported.
The Talzenna Xtandi trial addresses a critical need in prostate cancer care. Around 25 percent of metastatic cases involve HRR gene mutations, which are linked to poorer outcomes and limited response to standard treatments. Despite advances, up to 65 percent of mCSPC patients progress to a more aggressive stage within two years.
“Alterations in DNA damage repair genes, such as HRR genes, are found in approximately 25 percent of metastatic prostate cancers and associated with a worse prognosis and are less responsive to current standards of care, representing a group with a high unmet need,” said Jeff Legos, chief oncology officer, Pfizer.
“Talzenna plus Xtandi is already a standard of care in HRR gene-mutated metastatic castration-resistant prostate cancer, and these unprecedented results demonstrate the potential to deliver benefit earlier in the disease course. These findings underscore Pfizer’s leadership in precision medicine and commitment to bringing more personalized treatment options to people living with prostate cancer,” he added.
The TALAPRO-3 study enrolled 599 patients globally and tested Talzenna plus Xtandi against placebo plus Xtandi. Pfizer plans to present detailed findings at an upcoming medical meeting and discuss regulatory submissions with health authorities.
Key Data and Report Highlights
.jpg)
